10X Genomics Inc (TXG)

$19.28 -0.67 (-3.36%)
Market Cap 2.56B
Revenue (ttm) 610.79M
Net Income (ttm) -182.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -29.90%
Debt to Equity Ratio 0.00
Volume 2,755,800
Avg Vol 2,492,660
Day's Range N/A - N/A
Shares Out 126.55M
Stochastic %K 5%
Beta 2.18
Analysts Sell
Price Target $18.14

Company Profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, a...

Industry: Health Information Services
Sector: Healthcare
Phone: 925 401 7300
Address:
6230 Stoneridge Mall Road, Pleasanton, United States
ForgeFund
ForgeFund Feb. 4 at 9:49 AM
$TXG genomics, life science tools
0 · Reply
Oratory
Oratory Feb. 2 at 11:06 PM
$TXG "Investors should be cautious due to TXG's ongoing losses, reliance on volatile funding, competitive pressures, and past inefficient growth, all contributing to significant stock price risk."
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:40 PM
$TXG RSI: 50.97, MACD: 0.8371 Vol: 1.27, MA20: 20.84, MA50: 18.60 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Bates333
Bates333 Jan. 29 at 8:40 PM
$TXG bought
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 25 at 4:48 PM
$TXG 10x Genomics (NASDAQ:TXG) gives researchers superpowers to study disease at the cellular level. Learn how this genomics platform became a quiet heavyweight in biotech. https://biotechhealthx.com/biotech-news/this-stock-doesnt-cure-cancer-it-helps-scientists-figure-out-how-txg/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 12:33 AM
$TXG Share Price: $22.37 Contract Selected: Aug 21, 2026 $20 Calls Buy Zone: $5.35 – $6.62 Target Zone: $8.99 – $10.99 Potential Upside: 59% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WAJeff
WAJeff Jan. 23 at 1:53 AM
$TXG added this yesterday at $22.06 because I think it can return to $28 minimum and potentially even $36. Incredibly this was $7.14 on April 8 so someone buying there has already tripled their money.
4 · Reply
FloatingPisces
FloatingPisces Jan. 22 at 7:21 PM
$TXG no news. Any rumors?M for any up coming something?
0 · Reply
Sickmaiduck
Sickmaiduck Jan. 22 at 3:17 PM
$TXG 15million shares short. 9 days to cover. If this rally sustain we should see a massive short squeeze
2 · Reply
Sickmaiduck
Sickmaiduck Jan. 22 at 2:24 PM
$PACB $TXG both breaking out
0 · Reply
Latest News on TXG
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Jan 22, 2026, 4:05 PM EST - 12 days ago

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

10x Genomics, Inc. (TXG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:56 PM EST - 22 days ago

10x Genomics, Inc. (TXG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

Jan 12, 2026, 9:11 AM EST - 22 days ago

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

Jan 12, 2026, 9:10 AM EST - 22 days ago

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology

Jan 12, 2026, 9:00 AM EST - 22 days ago

Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results

Jan 11, 2026, 12:00 PM EST - 23 days ago

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

Jan 7, 2026, 7:05 AM EST - 4 weeks ago

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

CDNA

10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:05 PM EST - 5 weeks ago

10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference

New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium

Nov 18, 2025, 9:00 AM EST - 2 months ago

New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium

10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025

Nov 11, 2025, 4:05 PM EST - 3 months ago

10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025

10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 10:56 PM EST - 3 months ago

10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript

10x Genomics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 3 months ago

10x Genomics Reports Third Quarter 2025 Financial Results

Torex Gold Resources Inc. (TXG:CA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 11:56 AM EST - 3 months ago

Torex Gold Resources Inc. (TXG:CA) Q3 2025 Earnings Call Transcript

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research

Oct 29, 2025, 9:00 AM EDT - 3 months ago

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research

10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

Oct 20, 2025, 12:30 PM EDT - 3 months ago

10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 9, 2025, 4:05 PM EDT - 4 months ago

10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent

Oct 9, 2025, 8:00 AM EDT - 4 months ago

Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent

10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:14 PM EDT - 5 months ago

10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

Sep 9, 2025, 9:00 AM EDT - 5 months ago

CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 5 months ago

10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

Aug 19, 2025, 9:00 AM EDT - 6 months ago

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 4:13 AM EDT - 6 months ago

10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript

10x Genomics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 6 months ago

10x Genomics Reports Second Quarter 2025 Financial Results

10x Genomics to Acquire Scale Biosciences

Aug 7, 2025, 4:04 PM EDT - 6 months ago

10x Genomics to Acquire Scale Biosciences

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

Jul 17, 2025, 9:00 AM EDT - 7 months ago

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 10, 2025, 4:05 PM EDT - 7 months ago

10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

May 14, 2025, 4:05 PM EDT - 9 months ago

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:34 PM EDT - 9 months ago

10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript

10x Genomics Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 9 months ago

10x Genomics Reports First Quarter 2025 Financial Results

10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

Apr 30, 2025, 4:05 PM EDT - 9 months ago

10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

Vizgen Announces End of Litigation with 10x Genomics and Harvard University

Apr 3, 2025, 8:00 AM EDT - 10 months ago

Vizgen Announces End of Litigation with 10x Genomics and Harvard University

10x Genomics: Lower Cost Innovation May Drive A Rebound

Mar 20, 2025, 3:12 AM EDT - 11 months ago

10x Genomics: Lower Cost Innovation May Drive A Rebound

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

Mar 3, 2025, 4:05 PM EST - 1 year ago

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

Feb 23, 2025, 11:30 AM EST - 1 year ago

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 18, 2025, 4:05 PM EST - 1 year ago

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

Feb 13, 2025, 3:10 PM EST - 1 year ago

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 8:53 PM EST - 1 year ago

10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript

Trump's Cuts to Medical Research Are Hurting These Stocks

Feb 12, 2025, 7:19 PM EST - 1 year ago

Trump's Cuts to Medical Research Are Hurting These Stocks

ILMN PACB

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

Feb 12, 2025, 4:05 PM EST - 1 year ago

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Feb 6, 2025, 8:30 AM EST - 1 year ago

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Parse Biosciences Invalidates All 10x Genomics' Patent Claims Asserted Against Its Products

Feb 4, 2025, 8:59 AM EST - 1 year ago

Parse Biosciences Invalidates All 10x Genomics' Patent Claims Asserted Against Its Products

Spatial Omics Research Report 2023-2034: Market to reach $1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE

Jan 31, 2025, 6:34 AM EST - 1 year ago

Spatial Omics Research Report 2023-2034: Market to reach $1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:05 PM EST - 1 year ago

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

Dec 23, 2024, 4:05 PM EST - 1 year ago

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

BRKR

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

Nov 7, 2024, 4:05 PM EST - 1 year ago

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

Oct 31, 2024, 8:00 AM EDT - 1 year ago

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results

Oct 30, 2024, 2:41 PM EDT - 1 year ago

These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results

10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 8:04 PM EDT - 1 year ago

10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript

10x Genomics Reports Third Quarter 2024 Financial Results

Oct 29, 2024, 4:05 PM EDT - 1 year ago

10x Genomics Reports Third Quarter 2024 Financial Results

ForgeFund
ForgeFund Feb. 4 at 9:49 AM
$TXG genomics, life science tools
0 · Reply
Oratory
Oratory Feb. 2 at 11:06 PM
$TXG "Investors should be cautious due to TXG's ongoing losses, reliance on volatile funding, competitive pressures, and past inefficient growth, all contributing to significant stock price risk."
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:40 PM
$TXG RSI: 50.97, MACD: 0.8371 Vol: 1.27, MA20: 20.84, MA50: 18.60 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Bates333
Bates333 Jan. 29 at 8:40 PM
$TXG bought
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 25 at 4:48 PM
$TXG 10x Genomics (NASDAQ:TXG) gives researchers superpowers to study disease at the cellular level. Learn how this genomics platform became a quiet heavyweight in biotech. https://biotechhealthx.com/biotech-news/this-stock-doesnt-cure-cancer-it-helps-scientists-figure-out-how-txg/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 12:33 AM
$TXG Share Price: $22.37 Contract Selected: Aug 21, 2026 $20 Calls Buy Zone: $5.35 – $6.62 Target Zone: $8.99 – $10.99 Potential Upside: 59% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WAJeff
WAJeff Jan. 23 at 1:53 AM
$TXG added this yesterday at $22.06 because I think it can return to $28 minimum and potentially even $36. Incredibly this was $7.14 on April 8 so someone buying there has already tripled their money.
4 · Reply
FloatingPisces
FloatingPisces Jan. 22 at 7:21 PM
$TXG no news. Any rumors?M for any up coming something?
0 · Reply
Sickmaiduck
Sickmaiduck Jan. 22 at 3:17 PM
$TXG 15million shares short. 9 days to cover. If this rally sustain we should see a massive short squeeze
2 · Reply
Sickmaiduck
Sickmaiduck Jan. 22 at 2:24 PM
$PACB $TXG both breaking out
0 · Reply
endo3
endo3 Jan. 20 at 9:38 PM
$PACB today $PACB is up 6%, $UNH 2%, $ILMN 1.5%, $TXG is up by 7% While rest of the market tanked. Any rationale?
0 · Reply
RunnerSignals
RunnerSignals Jan. 20 at 9:12 PM
$PACB $SLS $CNTX $TXG $IMNM hit session lows but staged epic comebacks, closing well above their intraday bottoms
0 · Reply
DailyAnalysis
DailyAnalysis Jan. 20 at 8:12 PM
$TXG is a textbook dip buy. RSI at 47 offers runway, while CCI dipping to -122 signals a capitulation extreme. With Stochastic near 29, sellers are exhausted. Aggressively long for the reversal. @DailyAnalysis
0 · Reply
NotHopeJustFacts
NotHopeJustFacts Jan. 20 at 6:05 PM
$TXG stock over 80% up in 3 months, 42% up in 1 year, why ? it is not like their sales went up by that much... some figures were actually down compared to last fiscal year, better to buy some Puts options to be ready for the DUMP
1 · Reply
OptionRunners
OptionRunners Jan. 9 at 5:49 PM
$TXG ahead of next week's JPM conference
0 · Reply
ils85
ils85 Jan. 7 at 8:54 PM
$TXG
0 · Reply
POWELL_
POWELL_ Jan. 7 at 5:11 PM
$TXG price action has been good as of late
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 7 at 2:22 AM
$TXG RSI: 81.64, MACD: 0.3409 Vol: 0.97, MA20: 16.69, MA50: 16.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ils85
ils85 Jan. 5 at 11:29 PM
$TXG
0 · Reply
Smoothopera1or
Smoothopera1or Jan. 5 at 1:28 AM
$TXG Average Price Target: Analysts have a consensus price target for TXG ranging between $80 to $120. The average price target tends to hover around $100 to $110, depending on the analyst's outlook..
2 · Reply
Smoothopera1or
Smoothopera1or Jan. 5 at 1:26 AM
$TXG operates in the rapidly growing genomics and biotechnology sector, which is expected to continue expanding as gene sequencing becomes more advanced and widely used. The market for single-cell genomics, genetic research, and precision medicine is projected to grow significantly..
0 · Reply
bryantvsu
bryantvsu Dec. 25 at 6:40 PM
$TXG Posted last month.... bryantvsu Nov 09, 2025 5:15 PM $TXG Friends I look for a Monday pull back and then a run for higher highs. Per ZACK, 10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Can you see $19 or more soon? Options (-TXG260220C20) are moving ...$0.70 to $0.90 yesterday. Keep doing your own homework and smiling!
0 · Reply